Tools chosen: kalshi_direct claude_news claude_news gdelt_news wikipedia kalshi_related polymarket_related code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This hinges on whether wild poliovirus type 1 (WPV1) transmission in Pakistan and Afghanistan can be interrupted such that an entire calendar year (2025-2029) records zero reported WPV1 cases. 2024 had ~99 cases and 2025 has clearly non-zero counts, so realistically only 2027, 2028, or 2029 could qualify — and even after last-case interruption, GPEI's own goal timelines have slipped repeatedly. I need current case counts, GPEI target dates, funding/security conditions, and the market's own price anchor.

# Current state The market resolves YES if any calendar year 2024-2029 has zero global wild poliovirus type 1 (WPV1) cases. No year has come close: 2024 had ~94-99 cases, 2025 had ~38-45 cases (still declining but nonzero), and Afghanistan reported new cases as late as mid-2026 per GDELT. Kalshi prices this at 9.5% YES, up modestly over the past 30 days on improving case trends, but a genuine "zero" year remains distant given ongoing endemic transmission in Pakistan and Afghanistan. # Timeline of key events - 2021: Global WPV1 near-miss low of 6 cases (historical near-zero, did not reach zero) — confirmed (code_execution/historical data). - 2024: Resurgence to 94-99 global WPV1 cases (Pakistan ~74, Afghanistan ~25) — confirmed (WHO/outbreaknewstoday). - 2024-10: GPEI Polio Oversight Board extends WPV1 eradication target from 2026 to end-2027, cVDPV2 to 2029; budget raised to $6.9B — confirmed (polioeradication.org). - 2025 (through Oct 22): 38 WPV1 cases globally (down from 62 in same period 2024), all in Afghanistan/Pakistan — confirmed (healthpolicy-watch.news). - 2025-early: Trump administration cuts USAID funding (~$131M grant affected), forcing further GPEI strategy extension — confirmed (Borgen Project/news). - 2025 (full year): Pakistan ~30 cases (down from 74), Afghanistan ~21-22 cases; global 2025 total ~40-45 — reported (AP/WHO 44th meeting, wsls.com). - 2025-10-21: WHO warns of $1.7B funding shortfall through 2029, 30% GPEI budget cut for 2026 — confirmed (Al Jazeera/US News). - 2025-11: WHO 43rd IHR Committee notes Karachi zero cases in 2025 but continued environmental positivity; Gilgit-Baltistan reports first case in 8 years — confirmed (WHO). - 2025-12-08: Global leaders pledge $1.9B (incl. Gates Foundation $1.2B, Rotary $450M), cutting remaining funding gap to $440M — confirmed (CNN/US News). - 2026-03-04: WHO 44th IHR Committee reports 40 WPV1 cases in 2025 (9 Afghanistan, 31 Pakistan) and expresses optimism for interruption in H1 2026 — reported (WHO). - 2026 (Jan-Jul, per GDELT): Afghanistan reports new cases through mid-2026 (6 cases by June, rising further by July); Pakistan shows declining environmental positivity (13.1% by July) but continued vaccinator attacks — reported (GDELT/Khaama/Dunya News). # Event Will there be at least one calendar year (2024-2029) with zero globally reported wild poliovirus (WPV1) cases? # Outcomes to forecast - Yes - No # Kalshi market anchor **Current YES price: 9.50%** (ticker KXPOLIOELIM-30). 7-day change: +3.70%; 30-day change: +2.10%. Price range over lookback: 3.00%-10.70%. Average daily volume ~164 contracts (96 data points) — thin but liquid enough to reflect informed sentiment. Modest upward drift consistent with declining 2025 case counts, but market remains skeptical. # Sub-question answers 1. **2024/2025 case counts (Pakistan/Afghanistan)**: 2024: ~94-99 global (Pakistan ~74, Afghanistan ~25). 2025: ~38-45 global (Pakistan ~30-31, Afghanistan ~9-22, sources vary). [WHO, healthpolicy-watch, AP] 2. **Trend 2023-2025**: Declining after 2024 resurgence peak — 2025 roughly half of 2024 in both countries — but environmental surveillance still detects 80 WPV1-positive samples in 2025 (9 Afghanistan, 71 Pakistan), indicating persistent transmission reservoirs, not elimination. [id-ea.org, WHO 43rd Committee] 3. **GPEI target date**: Officially interruption of WPV1 transmission by 2027, cVDPV2 by 2029 (revised Oct 2024 from original 2026 goal) — a one-time major slip of at least one year already logged; WHO's March 2026 statement voices optimism for interruption in H1 2026, ahead of the formal 2027 target. [polioeradication.org, WHO 44th Committee] 4. **Reporting lag / base rate for zero years**: No explicit lag data given, but historical WPV1 series (2016-2025: 37,22,33,176,140,6,30,12,99,45) shows heavy overdispersion — a "near-zero" year (2021, 6 cases) has occurred but true zero has not been achieved in this dataset. [code_execution] 5. **Operational obstacles in 2025**: Taliban house-to-house vaccination ban persists in Afghanistan (~300,000 children consistently missed); Pakistan sees ongoing vaccinator/police killings (e.g., April 2026 Hangu attack, May 2026 KPK deaths) tied to militant (TTP) violence; GPEI faces 30% budget cut for 2026 and $1.7B gap through 2029, partly offset by $1.9B Dec 2025 pledges reducing gap to $440M. Net: funding situation improved late 2025 but security/access obstacles unresolved or worsening (new provinces like Gilgit-Baltistan affected). [amu.tv, Atlantic Council, Al Jazeera, CNN] 6. **Kalshi pricing / correlated markets**: KXPOLIOELIM-30 YES at 9.5%. No meaningful Polymarket correlate found (0 matches on polio/eradication/disease keywords). No other Kalshi polio series exists beyond this ticker. # Key facts (high-confidence, factual) 1. [WHO/healthpolicy-watch] 2025 WPV1 cases (~38-45) down roughly 50% from 2024 (~94-99), continuing decline trend. 2. [polioeradication.org] Official GPEI target for interrupting WPV1 transmission is now end-2027 (pushed back from 2026 in Oct 2024). 3. [Wikipedia/Polio in Pakistan] Only Afghanistan and Pakistan remain endemic; no zero-case year has occurred historically in this dataset (2016-2025 minimum was 6, in 2021). 4. [WHO 43rd/44th Committee] Environmental surveillance remains WPV1-positive in core reservoirs (Karachi, KP, Balochistan, southern Afghanistan) despite falling case counts. 5. [CNN/US News] $1.9B pledged Dec 2025 cut GPEI's 2022-2029 funding gap from $2.3B to $440M, partially mitigating US/UK/Germany funding cuts. # Cross-market signals - Kalshi related: Only this ticker (KXPOLIOELIM-30) exists in the polio series; no arbitrage market found. - Polymarket: No matching markets on polio/eradication/disease. - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - WHO's 44th Committee (Mar 2026) expresses "cautious optimism" that WPV1 transmission could be interrupted in H1 2026, contingent on progress in South KP, Karachi, and southern Afghanistan — but "interruption" ≠ a full zero-case calendar year, especially with reporting lags. - Independent quantitative modeling (code_execution) estimates P(≥1 zero-case year 2026-2029) ≈ 10-15%, with wide uncertainty (1%-38%) depending on assumed case-count dispersion; historical "lumpiness" argues against confident forecasts of true zero. - News synthesis (claude_news) concludes eradication "unlikely to hit zero cases before the official 2027 target—let alone reliably before 2030." # Directional lean per outcome - **Yes**: Supported by accelerating 2025 case decline (~50% drop), record funding pledges narrowing the gap, and WHO's stated optimism for interruption in H1 2026. Opposed by continued Taliban bans, vaccinator killings, new geographic spread (Gilgit-Baltistan), and persistent environmental positivity — plus GDELT reports of continuing 2026 cases in Afghanistan. - **No**: Supported by no historical zero-year ever occurring, quantitative modeling capping probability at ~10-15%, structural security/funding obstacles, and reporting lag risk near any true interruption. Kalshi's 9.5% price aligns closely with model estimates, suggesting market is well-calibrated toward "No" being the more likely outcome. # Gaps / unknowns - Reporting lag: unclear how quickly a "zero" year could be confirmed/certified given surveillance delays — a country could have zero *reported* cases in a calendar year while still having undetected transmission, complicating true elimination determination. - Discrepancy in 2025 case totals across sources (38 vs. 40 vs. 45) not fully reconciled. - GDELT timestamps show 2026 dates for ostensibly "future" events (e.g., WHO 44th Committee dated 2026-03-04), suggesting possible date artifacts in source data — treat exact chronology with caution. - No visibility into full-year 2026-2029 projections beyond partial 2026 data (through July per GDELT), which already shows continuing Afghan cases. # Calibration anchors - Kalshi current YES price: 9.5% (anchor). - Quantitative model estimate: ~10-15% central case for P(≥1 zero-case year before 2030). - Historical precedent: no zero WPV1 year in 2016-2025 dataset; closest was 6 cases (2021).

1. Both forecasts converge on identical 0.10/0.90 splits nearly matching the Kalshi anchor exactly, suggesting insufficient independent analysis — neither explores why the model's wide uncertainty band (1%-38%) might justify deviating from the point estimate, e.g., by weighting the tail scenario where WHO's "cautious optimism" for H1 2026 interruption actually materializes and compounds with the $1.9B funding infusion to produce a 2028/2029 zero year. 2. Both forecasters treat "2026 effectively eliminated" as settled based on partial GDELT data only through July, but the brief flags "GDELT timestamps show 2026 dates for ostensibly 'future' events... suggesting possible date artifacts" — neither forecast flags this data-quality caveat or discounts the Afghanistan mid-2026 case claim accordingly. 3. Neither forecast addresses the reporting-lag/certification gap explicitly raised in the brief ("a country could have zero *reported* cases in a calendar year while still having undetected transmission") — this cuts both ways (could make a nominal zero year easier to report even without true elimination, or harder to certify), and its omission is a missed nuance rather than just a modeling footnote. 4. Both narratives lean heavily on "no historical zero year has ever occurred" as if this were a hard constraint, but the historical series (37,22,33,176,140,6,30,12,99,45) is highly overdispersed and includes a 6-case year (2021) — with 2025 near 40 cases and a strong downward trajectory (~50% YoY decline), a mechanical extrapolation could plausibly hit single digits or zero by 2027-2028; neither forecast quantifies this trajectory-based scenario explicitly, instead deferring entirely to the outside-view model. 5. The funding narrative is likely under-weighted: the brief notes the 2022-2029 gap was cut from $2.3B to $440M by the Dec 2025 pledge, a major positive shock that both forecasts mention only in passing without adjusting probability mass toward 2028-2029 as increasingly plausible zero-years, especially since 3-4 calendar years (2027-2029) remain after the "eliminated" 2026. 6. Neither forecast considers cVDPV2 or classification ambiguity — the event is specifically about WPV1, and the brief notes GPEI's cVDPV2 target is 2029, raising a question of whether a "zero WPV1" year could occur even while cVDPV2 cases persist and dominate headlines, potentially causing miscounting or definitional disputes not addressed by either forecaster.

10% (medium confidence)

Yes: 10% No: 90%

2024 (~95 cases) and 2025 (~40 cases) are confirmed nonzero, and reported Afghan cases in 2026 make that year almost certainly nonzero too, leaving only 2027-2029 for a fully zero-case calendar year. Achieving that requires transmission interruption by late 2026/early 2027 plus a clean subsequent calendar year — materially harder than 'interruption,' and history shows a 2021 near-zero (6 cases) immediately rebounding to 30, 12, then 99 cases, illustrating how fragile near-elimination is. The critique's upside points (strong ~50% YoY decline, $1.9B Dec 2025 pledges closing the funding gap to $440M, WHO's optimism about H1 2026 interruption) are real and justify not going below the market, but they are offset by persistent environmental positivity in Karachi/KP/southern Afghanistan, the Taliban house-to-house ban, vaccinator killings, and geographic spread to new areas like Gilgit-Baltistan. The independent model (~10-15% central, wide band) and Kalshi's 9.5% converge, so I settle essentially at the anchor with a slight nod to the improving trajectory.

Total pipeline time: 318.1s